Terms: = Rhabdomyosarcoma AND MYC, c-Myc, 4609, ENSG00000136997 AND Treatment
24 results:
1. Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma.
Walker RL; Hornicek FJ; Duan Z
Biochem Pharmacol; 2024 Aug; 226():116342. PubMed ID: 38848777
[TBL] [Abstract] [Full Text] [Related]
2. Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in rhabdomyosarcoma treatment.
Marchesi I; Fais M; Fiorentino FP; Bordoni V; Sanna L; Zoroddu S; Bagella L
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408939
[TBL] [Abstract] [Full Text] [Related]
3. Functional impact and targetability of
Choo F; Odintsov I; Nusser K; Nicholson KS; Davis L; Corless CL; Stork L; Somwar R; Ladanyi M; Davis JL; Davare MA
Cold Spring Harb Mol Case Stud; 2022 Jan; 8(1):. PubMed ID: 35012940
[TBL] [Abstract] [Full Text] [Related]
4. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 rhabdomyosarcoma Cells.
Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
[TBL] [Abstract] [Full Text] [Related]
5. Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells.
Huot M; Caron M; Richer C; Djibo R; Najmanovich R; St-Onge P; Sinnett D; Raynal NJM
Cancer Chemother Pharmacol; 2021 Nov; 88(5):845-856. PubMed ID: 34331108
[TBL] [Abstract] [Full Text] [Related]
6. Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype.
Rossetti A; Petragnano F; Milazzo L; Vulcano F; Macioce G; Codenotti S; Cassandri M; Pomella S; Cicchetti F; Fasciani I; Antinozzi C; Di Luigi L; Festuccia C; De Felice F; Vergine M; Fanzani A; Rota R; Maggio R; Polimeni A; Tombolini V; Gravina GL; Marampon F
Int J Radiat Biol; 2021; 97(7):943-957. PubMed ID: 33979259
[TBL] [Abstract] [Full Text] [Related]
7. The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells.
Laszig S; Boedicker C; Weiser T; Knapp S; Fulda S
Cancer Lett; 2020 Aug; 486():46-57. PubMed ID: 32445837
[TBL] [Abstract] [Full Text] [Related]
8. Co-inhibition of BET proteins and PI3Kα triggers mitochondrial apoptosis in rhabdomyosarcoma cells.
Boedicker C; Hussong M; Grimm C; Dolgikh N; Meister MT; Enßle JC; Wanior M; Knapp S; Schweiger MR; Fulda S
Oncogene; 2020 May; 39(19):3837-3852. PubMed ID: 32161312
[TBL] [Abstract] [Full Text] [Related]
9. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
[TBL] [Abstract] [Full Text] [Related]
10. GADD45A and CDKN1A are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway.
Kleinsimon S; Longmuss E; Rolff J; Jäger S; Eggert A; Delebinski C; Seifert G
Sci Rep; 2018 Apr; 8(1):5750. PubMed ID: 29636527
[TBL] [Abstract] [Full Text] [Related]
11. c-myc promotes tumor proliferation and anti‑apoptosis by repressing p21 in rhabdomyosarcomas.
Zhang J; Song N; Zang D; Yu J; Li J; Di W; Guo R; Zhao W; Wang H
Mol Med Rep; 2017 Oct; 16(4):4089-4094. PubMed ID: 28765944
[TBL] [Abstract] [Full Text] [Related]
12. c-myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal rhabdomyosarcoma Cell Lines.
Gravina GL; Festuccia C; Popov VM; Di Rocco A; Colapietro A; Sanità P; Monache SD; Musio D; De Felice F; Di Cesare E; Tombolini V; Marampon F
Radiat Res; 2016 Apr; 185(4):411-22. PubMed ID: 27104757
[TBL] [Abstract] [Full Text] [Related]
13. The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.
Bid HK; Phelps DA; Xaio L; Guttridge DC; Lin J; London C; Baker LH; Mo X; Houghton PJ
Mol Cancer Ther; 2016 May; 15(5):1018-28. PubMed ID: 26908627
[TBL] [Abstract] [Full Text] [Related]
14. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy.
Tonelli R; McIntyre A; Camerin C; Walters ZS; Di Leo K; Selfe J; Purgato S; Missiaglia E; Tortori A; Renshaw J; Astolfi A; Taylor KR; Serravalle S; Bishop R; Nanni C; Valentijn LJ; Faccini A; Leuschner I; Formica S; Reis-Filho JS; Ambrosini V; Thway K; Franzoni M; Summersgill B; Marchelli R; Hrelia P; Cantelli-Forti G; Fanti S; Corradini R; Pession A; Shipley J
Clin Cancer Res; 2012 Feb; 18(3):796-807. PubMed ID: 22065083
[TBL] [Abstract] [Full Text] [Related]
15. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.
Marampon F; Gravina GL; Di Rocco A; Bonfili P; Di Staso M; Fardella C; Polidoro L; Ciccarelli C; Festuccia C; Popov VM; Pestell RG; Tombolini V; Zani BM
Mol Cancer Ther; 2011 Jan; 10(1):159-68. PubMed ID: 21220498
[TBL] [Abstract] [Full Text] [Related]
16. Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells.
Stepulak A; Rzeski W; Sifringer M; Brocke K; Gratopp A; Kupisz K; Turski L; Ikonomidou C
Cancer Biol Ther; 2008 Oct; 7(10):1685-93. PubMed ID: 18836303
[TBL] [Abstract] [Full Text] [Related]
17. mycN deregulation as a potential target for novel therapies in rhabdomyosarcoma.
Morgenstern DA; Anderson J
Expert Rev Anticancer Ther; 2006 Feb; 6(2):217-24. PubMed ID: 16445374
[TBL] [Abstract] [Full Text] [Related]
18. Effects of transforming growth factor beta 1 on the growth of rhabdomyosarcoma cell line RD.
Ye L; Zhang HY; Wang H; Yang GH; Bu H; Zhang L; Wang SL
Chin Med J (Engl); 2005 Apr; 118(8):678-86. PubMed ID: 15899124
[TBL] [Abstract] [Full Text] [Related]
19. The mycN oncoprotein as a drug development target.
Lu X; Pearson A; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
[TBL] [Abstract] [Full Text] [Related]
20. Risk-based management: current concepts of treating malignant solid tumors of childhood.
Grosfeld JL
J Am Coll Surg; 1999 Oct; 189(4):407-25. PubMed ID: 10509467
[TBL] [Abstract] [Full Text] [Related]
[Next]
